Drug intelligence / Profile preview

Anseren

Development stage: Unknown
Lead developer: Forte Biosciences
Modality: Small Molecules
Administration: Oral

Overview

Anseren is a benzodiazepine anxiolytic medication containing the active ingredient ketazolam. Marketed by Phoenix Laboratories, it acts as a positive allosteric modulator of the GABA-A receptor at the benzodiazepine binding site. By enhancing the inhibitory effects of gamma-aminobutyric acid (GABA), it produces anxiolytic, sedative, and muscle-relaxant effects. Anseren is primarily indicated for the treatment of anxiety, tension, and associated somatic or psychiatric symptoms, as well as severe or disabling insomnia. It is available in oral capsule formulations (15 mg, 30 mg, and 45 mg) and is marketed in several European countries, including Italy and Ireland.

Brand names: AnserenAnsietenAnsietilMarcenSedativalSedotimeSolatranUnakalm
Other names: ketazolam

Targets

GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on Anseren.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anseren.

Explore the full profile